Govwatch

Introduced

In Committee

3

Passed One Chamber

4

Passed Both

5

Signed into Law

Sponsor

Jack Reed

Democrat · RI · Senator

Votes with party: 58.0% (319 recorded votes)

Full profile: /officials/R000122

Source: Congress.gov · FEC

Cosponsors (3)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1093)

2026-03-17

Source: Congress.gov

Committee Activity

Currently in

Senate Committee on Health, Education, Labor, and PensionsReferred To · 2026-03-17

Previously

Health, Education, Labor, and Pensions CommitteeReferred To · 2026-03-17

Plain-English Summary

This bill would reauthorize federal funding and oversight for stem cell research and therapies, allowing scientists to continue studying how stem cells might treat diseases like Parkinson's, diabetes, and spinal cord injuries. The legislation would likely set funding levels, establish guidelines for what types of stem cell research can receive government money, and clarify rules for developing stem cell-based treatments that patients could eventually use. The bill affects medical researchers, pharmaceutical companies developing new treatments, and patients who might benefit from stem cell therapies in the future.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 4109 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 4109 To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES March 17, 2026 Mr. Reed (for himself, Mr. Scott of South Carolina, Ms. Smith, and Mr. Lankford) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Stem Cell Therapeutic and Research Reauthorization Act of 2026''. SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM. Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended-- (1) by striking ``appropriated $31,009,000'' and inserting the following: ``appropriated-- ``(1) $31,009,000''; (2) in paragraph (1), as so inserted, by striking the period at the end and inserting ``; and''; and (3) by adding at the end the following: ``(2) $33,009,000 for each of fiscal years 2027 through 2031.''. SEC. 3. CORD BLOOD INVENTORY. Section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking ``2026'' and inserting ``2031''. <all>

Open clean-text view Read on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.